The annual BHF conference is taking place in Cape Town from 14 -17 May 2023

By HEOR Staff Writer

February 8, 2023

The annual BHF conference is taking place in Cape Town from 14 -17 May 2023. Networking, collaboration and learning about emerging healthcare issues, innovation and industry action, and discussions regarding what’s next.

Reference url

Recent Posts

Advancing the Biosimilar Approval Framework: A Shift Towards Analytical Comparability

By HEOR Staff Writer

April 6, 2026

Below we highlight how the European Medicines Agency (EMA) is reshaping the biosimilar approval framework by prioritising advanced analytical characterisation over traditional comparative efficacy studies. A recently finalized reflection paper outlines a science-based, tailored clinical develo...
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role in Treating PD-L1-P...
Immunotherapy ovarian cancer treatment has taken a major step forward in Europe. The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary...
Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Treatment

By João L. Carapinha

April 3, 2026

Reimbursement Bladder Cancer advances with the assignment of a permanent HCPCS J-code for INLEXZOâ„¢ (gemcitabine intravesical system), effective April 1, 2026. This standardized billing code simplifies reimbursement bladder cancer treatment for adult patients with BCG-unresponsive non-muscle invas...